JP6778809B2 - A method for producing a base for a patch and a method for producing a patch using a base obtained thereby. - Google Patents
A method for producing a base for a patch and a method for producing a patch using a base obtained thereby. Download PDFInfo
- Publication number
- JP6778809B2 JP6778809B2 JP2019210348A JP2019210348A JP6778809B2 JP 6778809 B2 JP6778809 B2 JP 6778809B2 JP 2019210348 A JP2019210348 A JP 2019210348A JP 2019210348 A JP2019210348 A JP 2019210348A JP 6778809 B2 JP6778809 B2 JP 6778809B2
- Authority
- JP
- Japan
- Prior art keywords
- base
- patch
- mass
- producing
- gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 30
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 76
- 229920001577 copolymer Polymers 0.000 claims description 45
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 41
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 41
- 108010010803 Gelatin Proteins 0.000 claims description 38
- 229920000159 gelatin Polymers 0.000 claims description 38
- 239000008273 gelatin Substances 0.000 claims description 38
- 235000019322 gelatine Nutrition 0.000 claims description 38
- 235000011852 gelatine desserts Nutrition 0.000 claims description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 34
- 239000011505 plaster Substances 0.000 claims description 30
- 229920002125 Sokalan® Polymers 0.000 claims description 18
- 239000004584 polyacrylic acid Substances 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- YIWUKEYIRIRTPP-UHFFFAOYSA-N 2-ethylhexan-1-ol Chemical group CCCCC(CC)CO YIWUKEYIRIRTPP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 3
- 235000019645 odor Nutrition 0.000 description 39
- 239000000853 adhesive Substances 0.000 description 22
- 230000001070 adhesive effect Effects 0.000 description 22
- 239000000839 emulsion Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- -1 poly (oxyethylene) nonylphenyl ether Polymers 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000001953 sensory effect Effects 0.000 description 9
- 239000002826 coolant Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 229910000831 Steel Inorganic materials 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000010959 steel Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 229920001748 polybutylene Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- TZZAKSLHHIJRLL-UHFFFAOYSA-N 4-hydroxy-3-methoxybenzamide Chemical compound COC1=CC(C(N)=O)=CC=C1O TZZAKSLHHIJRLL-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- XQVWYOYUZDUNRW-UHFFFAOYSA-N N-Phenyl-1-naphthylamine Chemical compound C=1C=CC2=CC=CC=C2C=1NC1=CC=CC=C1 XQVWYOYUZDUNRW-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- YWXYYJSYQOXTPL-JGWLITMVSA-N [(3r,3ar,6s,6as)-3-hydroxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-JGWLITMVSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-M nonanoate Chemical compound CCCCCCCCC([O-])=O FBUKVWPVBMHYJY-UHFFFAOYSA-M 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920003207 poly(ethylene-2,6-naphthalate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Adhesives Or Adhesive Processes (AREA)
Description
本発明は、貼付剤用基剤の製造方法及びそれにより得られる基剤を用いる貼付剤の製造方法に関し、より詳しくは、ゼラチン及びポリビニルアルコールを含有する貼付剤用基剤の製造方法及びそれにより得られる基剤を用いる貼付剤の製造方法に関する。 The present invention relates to a method for producing a base for a patch and a method for producing a patch using a base obtained by the method, and more particularly, a method for producing a base for a patch containing gelatin and polyvinyl alcohol and a method for producing the same. The present invention relates to a method for producing a patch using the obtained base.
貼付剤用基剤には、基剤層の高い水分含量や優れた保形性及び凝集性を確保するために、ゼラチン、ポリアクリル酸、ポリアクリル酸塩、ポリビニルアルコール等の水溶性高分子が含まれている。また、このような貼付剤用基剤においては、冷却効果を発現させるために、L−メントール等の清涼化剤が含まれている(例えば、国際公開第2006/090782号(特許文献1)及び国際公開第2015/025935号(特許文献2))。 The base for the patch contains water-soluble polymers such as gelatin, polyacrylic acid, polyacrylic acid salt, and polyvinyl alcohol in order to ensure the high water content of the base layer and excellent shape retention and cohesiveness. include. In addition, such a base for a patch contains a cooling agent such as L-menthol in order to exert a cooling effect (for example, International Publication No. 2006/090782 (Patent Document 1) and Patent Document 1). International Publication No. 2015/025935 (Patent Document 2)).
しかしながら、従来の貼付剤用基剤においては、清涼化剤として用いられているL−メントールの強い刺激臭がまれに問題になる場合があり、L−メントールに代わる無臭の清涼化剤として、L−メンチルグリセリルエーテルが知られており、その誘導体も提案されている(例えば、特開平9−217083号公報(特許文献3))。 However, in the conventional base for patches, the strong pungent odor of L-menthol used as a refreshing agent may rarely become a problem, and as an odorless cooling agent instead of L-menthol, L -Menthol glyceryl ether is known, and a derivative thereof has also been proposed (for example, JP-A-9-217803 (Patent Document 3)).
しかしながら、従来の貼付剤用基剤において、清涼化剤をL−メントールからL−メンチルグリセリルエーテルに変更しても、未だ、不快な臭いが発生することを本発明者らは見出した。 However, the present inventors have found that even if the refreshing agent is changed from L-menthol to L-menthylglyceryl ether in the conventional base for patches, an unpleasant odor is still generated.
本発明は、上記従来技術の有する課題に鑑みてなされたものであり、清涼化剤としてL−メンチルグリセリルエーテルを用いた場合であっても、基剤の粘着力を保持しつつ、不快な臭いの発生が抑制された貼付剤用基剤及びそれを用いた貼付剤を提供することを目的とする。 The present invention has been made in view of the above-mentioned problems of the prior art, and even when L-menthylglyceryl ether is used as a cooling agent, it has an unpleasant odor while maintaining the adhesive strength of the base. It is an object of the present invention to provide a patch base for which the occurrence of the above is suppressed and a patch using the same.
本発明者らは、上記目的を達成すべく鋭意研究を重ねた結果、清涼化剤としてL−メンチルグリセリルエーテルを含有する従来の貼付剤用基剤において、不快な臭いを発生する原因が基剤に含まれるゼラチン及びポリビニルアルコールであることを見出し、さらに、基剤にポリ(アクリル酸メチル/アクリル酸2−エチルヘキシル)共重合体を配合することによって、ゼラチン及びポリビニルアルコールから発生する不快な臭いが抑制されることを見出し、本発明を完成するに至った。 As a result of intensive studies to achieve the above object, the present inventors have found that the cause of generating an unpleasant odor in a conventional patch base containing L-mentylglyceryl ether as a cooling agent is the base. By adding a poly (methyl acrylate / 2-ethylhexyl acrylate) copolymer to the base, an unpleasant odor generated from gelatin and polyvinyl alcohol can be obtained. It was found that it was suppressed, and the present invention was completed.
すなわち、本発明の貼付剤用基剤の製造方法は、ゼラチン、ポリビニルアルコール、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体、及びL−メンチルグリセリルエーテルを含有する基剤の製造方法であって、
該基剤の全質量に対して、
前記ゼラチンの含有量が1.5〜6質量%であり、
前記ポリビニルアルコールの含有量が0.5〜8質量%であり、
前記アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量が0.5〜13質量%であるように、
ゼラチン、ポリビニルアルコール、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体、及びL−メンチルグリセリルエーテルを混合する方法である。
That is, the method for producing a base for a patch of the present invention is a method for producing a base containing gelatin, polyvinyl alcohol, a 2-ethylhexyl copolymer of methyl acrylate / acrylate, and L-menthylglyceryl ether. ,
With respect to the total mass of the base
The gelatin content is 1.5 to 6% by mass.
The content of the polyvinyl alcohol is 0.5 to 8% by mass.
So that the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer is 0.5 to 13% by mass.
This is a method of mixing gelatin, polyvinyl alcohol, 2-ethylhexyl acrylate copolymer, and L-menthylglyceryl ether.
このような本発明の貼付剤用基剤の製造方法においては、ポリアクリル酸及びポリアクリル酸中和物からなる群から選択される少なくとも1種の粘着剤を更に混合することが好ましい。 In such a method for producing a base for a patch of the present invention, it is preferable to further mix at least one pressure-sensitive adhesive selected from the group consisting of polyacrylic acid and a neutralized polyacrylic acid.
また、本発明の貼付剤の製造方法は、支持体上に、基剤と薬物とを含有する膏体層を備える貼付剤の製造方法であって、
前記本発明の貼付剤用基剤の製造方法により前記基剤を調製し、該基剤と前記薬物とを含有する前記膏体層を形成し、該膏体層上に前記支持体を積層する方法である。このような本発明の貼付剤の製造方法においては、前記基剤と前記薬物とを含有する膏体を調製し、該膏体を剥離ライナー上に展延することによって、前記膏体層を形成することが好ましい。
Further, the method for producing a patch of the present invention is a method for producing a patch having a plaster layer containing a base and a drug on a support.
The base is prepared by the method for producing a base for a patch of the present invention, the plaster layer containing the base and the drug is formed, and the support is laminated on the plaster layer. The method. In such a method for producing a patch of the present invention, a plaster containing the base and the drug is prepared, and the plaster is spread on a release liner to form the plaster layer. It is preferable to do so.
本発明によれば、清涼化剤としてL−メンチルグリセリルエーテルを用いた場合であっても、基剤の粘着力を保持しつつ、不快な臭いの発生が抑制された貼付剤用基剤及びそれを用いた貼付剤を提供することが可能となる。 According to the present invention, even when L-menthylglyceryl ether is used as a cooling agent, a patch base and a patch base in which the generation of an unpleasant odor is suppressed while maintaining the adhesive strength of the base. It becomes possible to provide a patch using the above.
以下、本発明をその好適な実施形態に即して詳細に説明する。 Hereinafter, the present invention will be described in detail according to its preferred embodiment.
先ず、本発明の貼付剤用基剤の製造方法について説明する。本発明の貼付剤用基剤の製造方法は、ゼラチン、ポリビニルアルコール、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体、及びL−メンチルグリセリルエーテルを含有する基剤の製造方法であり、
該基剤の全質量に対して、
前記ゼラチンの含有量が1.5〜6質量%であり、
前記ポリビニルアルコールの含有量が0.5〜8質量%であり、
前記アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量が0.5〜13.0質量%であるように、
ゼラチン、ポリビニルアルコール、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体、及びL−メンチルグリセリルエーテルを混合する方法である。
First, a method for producing a base for a patch of the present invention will be described. The method for producing a base for a patch of the present invention is a method for producing a base containing gelatin, polyvinyl alcohol, a 2-ethylhexyl copolymer of methyl acrylate / 2-ethylhexyl acrylate, and L-menthylglyceryl ether.
With respect to the total mass of the base
The gelatin content is 1.5 to 6% by mass.
The content of the polyvinyl alcohol is 0.5 to 8% by mass.
So that the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer is 0.5 to 13.0% by mass.
This is a method of mixing gelatin, polyvinyl alcohol, 2-ethylhexyl acrylate copolymer, and L-menthylglyceryl ether.
本発明に用いられるゼラチンとしては、一般に貼付剤に用いられるものであれば、特に制限はない。本発明によって得られる貼付剤用基剤において、このゼラチンの含有量は、基剤の全質量に対して1.5〜6質量%である。ゼラチンの含有量が1.5質量%未満になると、基剤にアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体を配合しなくても、ゼラチンに由来する不快な臭いは発生しない。このため、ゼラチンに由来する不快な臭いの発生を抑制するという目的で、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体を基剤に配合する場合には、ゼラチンの含有量が1.5質量%以上(好ましくは2質量%以上)の基剤を対象とする必要がある。他方、ゼラチンの含有量が6質量%を超えると、基剤の粘着力が低下する。また、基剤の粘着力を十分に確保するという観点から、ゼラチンの含有量の上限としては5質量%以下が好ましく、4質量%以下がより好ましい。 The gelatin used in the present invention is not particularly limited as long as it is generally used as a patch. In the patch base obtained by the present invention, the content of this gelatin is 1.5 to 6% by mass with respect to the total mass of the base. When the gelatin content is less than 1.5% by mass, the unpleasant odor derived from gelatin does not occur even if the methyl acrylate / 2-ethylhexyl acrylate copolymer is not added to the base. Therefore, when a methyl acrylate / 2-ethylhexyl acrylate copolymer is added to the base for the purpose of suppressing the generation of an unpleasant odor derived from gelatin, the gelatin content is 1.5% by mass. It is necessary to target a base of% or more (preferably 2% by mass or more). On the other hand, when the gelatin content exceeds 6% by mass, the adhesive strength of the base is lowered. Further, from the viewpoint of sufficiently ensuring the adhesive strength of the base, the upper limit of the gelatin content is preferably 5% by mass or less, more preferably 4% by mass or less.
本発明に用いられるポリビニルアルコールとしては、一般に貼付剤に用いられるものであれば、特に制限はない。本発明によって得られる貼付剤用基剤において、このポリビニルアルコールの含有量は、基剤の全質量に対して0.5〜8質量%である。ポリビニルアルコールの含有量が0.5質量%未満になると、基剤にアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体を配合しなくても、ポリビニルアルコールに由来する不快な臭いは発生しない。このため、ポリビニルアルコールに由来する不快な臭いの発生を抑制するという目的で、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体を基剤に配合する場合には、ポリビニルアルコールの含有量が0.5質量%以上(好ましくは1質量%以上)の基剤を対象とする必要がある。他方、ポリビニルアルコールの含有量が8質量%を超えると、基剤の粘着力が高くなりすぎ、剥離時の痛みを許容できない。また、剥離時の痛みを許容できる適度な粘着力を確保するという観点から、ポリビニルアルコールの含有量としては7.5質量%以下が好ましい。 The polyvinyl alcohol used in the present invention is not particularly limited as long as it is generally used as a patch. In the patch base obtained by the present invention, the content of this polyvinyl alcohol is 0.5 to 8% by mass with respect to the total mass of the base. When the content of polyvinyl alcohol is less than 0.5% by mass, the unpleasant odor derived from polyvinyl alcohol does not occur even if the methyl acrylate / 2-ethylhexyl acrylate copolymer is not added to the base. Therefore, when a methyl acrylate / 2-ethylhexyl acrylate copolymer is blended as a base for the purpose of suppressing the generation of an unpleasant odor derived from polyvinyl alcohol, the content of polyvinyl alcohol is 0. It is necessary to target a base of 5% by mass or more (preferably 1% by mass or more). On the other hand, if the content of polyvinyl alcohol exceeds 8% by mass, the adhesive strength of the base becomes too high, and pain at the time of peeling cannot be tolerated. Further, from the viewpoint of ensuring an appropriate adhesive force that can tolerate pain at the time of peeling, the content of polyvinyl alcohol is preferably 7.5% by mass or less.
本発明に用いられるアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体は、アクリル酸メチルとアクリル酸2−エチルヘキシルとの共重合体である。このアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体を配合することによって、ゼラチン及びポリビニルアルコールに由来する不快な臭いの発生を抑制することができる。本発明によって得られる貼付剤用基剤において、このようなアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量は、基剤の全質量に対して0.5〜13質量%である。アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量が0.5質量%未満になると、ゼラチン及びポリビニルアルコールに由来する不快な臭いの発生を抑制することができない。他方、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量が13質量%を超えると、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体自体の臭いが発生する。また、ゼラチン及びポリビニルアルコールに由来する不快な臭いやアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体自体の臭いの発生を確実に抑制するという観点から、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量としては0.6〜12質量%が好ましく、0.6〜10質量%がより好ましい。 The methyl acrylate / 2-ethylhexyl acrylate copolymer used in the present invention is a copolymer of methyl acrylate and 2-ethylhexyl acrylate. By blending this methyl acrylate / 2-ethylhexyl acrylate copolymer, the generation of an unpleasant odor derived from gelatin and polyvinyl alcohol can be suppressed. In the base for a patch obtained by the present invention, the content of such a methyl acrylate / 2-ethylhexyl acrylate copolymer is 0.5 to 13% by mass with respect to the total mass of the base. When the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer is less than 0.5% by mass, the generation of an unpleasant odor derived from gelatin and polyvinyl alcohol cannot be suppressed. On the other hand, when the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer exceeds 13% by mass, the odor of the methyl acrylate / 2-ethylhexyl acrylate copolymer itself is generated. Further, from the viewpoint of surely suppressing the generation of unpleasant odors derived from gelatin and polyvinyl alcohol and the odors of the methyl acrylate / 2-ethylhexyl acrylate copolymer itself, the copolymer weight of methyl acrylate / 2-ethylhexyl acrylate. The content of the coalescence is preferably 0.6 to 12% by mass, more preferably 0.6 to 10% by mass.
本発明において、前記アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体は、貼付剤用基剤の製造時に、水に分散された水性エマルジョンの状態で配合されることが好ましい。この場合、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体のエマルジョンの固形分基準の含有量が本発明に用いられるアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量となる。このようなアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の水性エマルジョンとしては、水及びアクリル酸メチル・アクリル酸2−エチルヘキシル共重合体のほか、界面活性剤及び/又は保護コロイド剤を更に含有するものであることが好ましく、前記界面活性剤及び/又は保護コロイド剤としては、ポリ(オキシエチレン)ノニルフェニルエーテルが好ましい。このため、本発明によって得られる貼付剤用基剤には、前記水性エマルジョンに由来する界面活性剤及び/又は保護コロイド剤が更に含まれていてもよい。前記界面活性剤及び/又は保護コロイド剤(好ましくは、ポリ(オキシエチレン)ノニルフェニルエーテル)を更に含有する場合、その合計含有量としては、基剤の全質量に対して0.01〜0.5質量%が好ましい。 In the present invention, the methyl acrylate / 2-ethylhexyl acrylate copolymer is preferably blended in the form of an aqueous emulsion dispersed in water at the time of producing a base for a patch. In this case, the solid content of the emulsion of the methyl acrylate / 2-ethylhexyl acrylate copolymer is the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer used in the present invention. The aqueous emulsion of such a methyl acrylate / 2-ethylhexyl acrylate copolymer further contains a surfactant and / or a protective colloidal agent in addition to water and a 2-ethylhexyl acrylate copolymer. As the surfactant and / or protective colloidal agent, poly (oxyethylene) nonylphenyl ether is preferable. Therefore, the base for the patch obtained by the present invention may further contain a surfactant and / or a protective colloidal agent derived from the aqueous emulsion. When the surfactant and / or protective colloidal agent (preferably poly (oxyethylene) nonylphenyl ether) is further contained, the total content thereof is 0.01 to 0. With respect to the total mass of the base. 5% by mass is preferable.
本発明によって得られる貼付剤用基剤においては、清涼化剤としてL−メンチルグリセリルエーテルが含まれている。このようなL−メンチルグリセリルエーテルとしては、一般に貼付剤に用いられるものであれば、特に制限はない。このL−メンチルグリセリルエーテルは、無臭であるため、本発明によって得られる貼付剤用基剤及びそれを用いた貼付剤からは、L−メントールのような刺激臭は発生しない。本発明によって得られる貼付剤用基剤において、このL−メンチルグリセリルエーテルの含有量としては、基剤の全質量に対して0.5〜7質量%が好ましい。 The patch base obtained by the present invention contains L-menthylglyceryl ether as a cooling agent. The L-mentyl glyceryl ether is not particularly limited as long as it is generally used as a patch. Since this L-menthylglyceryl ether is odorless, a pungent odor like L-menthol is not generated from the base for a patch obtained by the present invention and a patch using the same. In the patch base obtained by the present invention, the content of the L-menthylglyceryl ether is preferably 0.5 to 7% by mass with respect to the total mass of the base.
また、本発明によって得られる貼付剤用基剤においては、ポリアクリル酸及びポリアクリル酸中和物からなる群から選択される少なくとも1種の粘着剤を更に含有していることが好ましい。これにより、基剤の粘着力が向上する。 Further, it is preferable that the base for a patch obtained by the present invention further contains at least one pressure-sensitive adhesive selected from the group consisting of polyacrylic acid and a neutralized polyacrylic acid. This improves the adhesive strength of the base.
前記ポリアクリル酸としては一般に貼付剤に用いられるものであれば、特に制限はない。本発明によって得られる貼付剤用基剤において、このポリアクリル酸の含有量としては、基剤の全質量に対して1〜5質量%が好ましい。これにより、基剤の粘着力が向上するとともに、膏体層の成形性及び保形性が向上する傾向にあり、さらに、膏体層の硬度が高くなりにくく、皮膚への密着性が向上する傾向にある。 The polyacrylic acid is not particularly limited as long as it is generally used as a patch. In the patch base obtained by the present invention, the content of this polyacrylic acid is preferably 1 to 5% by mass with respect to the total mass of the base. As a result, the adhesive strength of the base tends to be improved, the moldability and shape retention of the plaster layer tend to be improved, the hardness of the plaster layer is less likely to increase, and the adhesion to the skin is improved. There is a tendency.
前記ポリアクリル酸中和物としては一般に貼付剤に用いられるものであれば特に制限はなく、例えば、ナトリウム塩、カリウム塩、カルシウム塩、アンモニウム塩等のポリアクリル酸塩が挙げられる。このようなポリアクリル酸中和物は、部分中和物であっても完全中和物であっても、これらの混合物であってもよいが、基剤の粘着力がより向上するという観点から、ポリアクリル酸の部分中和物が好ましい。このポリアクリル酸の部分中和物は、1つのポリマー鎖においてアクリル酸に由来する構造単位とアクリル酸塩に由来する構造単位とが任意の割合で存在しているものであり、1つのポリマー鎖中のカルボキシ基の20モル%以上が中和されていることが好ましい。このポリアクリル酸中和物の含有量としては、基剤の全質量に対して1〜5質量%が好ましい。これにより、基剤の粘着力が向上するとともに、膏体層の成形性及び保形性が向上する傾向にある。 The neutralized polyacrylic acid is not particularly limited as long as it is generally used as a patch, and examples thereof include polyacrylates such as sodium salt, potassium salt, calcium salt, and ammonium salt. Such a neutralized polyacrylic acid may be a partially neutralized product, a completely neutralized product, or a mixture thereof, but from the viewpoint of further improving the adhesive strength of the base. , A partially neutralized product of polyacrylic acid is preferable. In this partially neutralized product of polyacrylic acid, structural units derived from acrylic acid and structural units derived from acrylate are present in an arbitrary ratio in one polymer chain, and one polymer chain is present. It is preferable that 20 mol% or more of the carboxy groups in the medium are neutralized. The content of the neutralized polyacrylic acid is preferably 1 to 5% by mass with respect to the total mass of the base. As a result, the adhesive strength of the base is improved, and the moldability and shape retention of the plaster layer tend to be improved.
また、本発明によって得られる貼付剤がパップ剤である場合には、本発明によって得られる貼付剤用基剤には水(精製水)が含まれている。水の含有量としては、基剤の全質量に対して20〜95質量%が好ましく、25〜90質量%がより好ましい。これにより、ポリアクリル酸及びポリアクリル酸中和物による粘着力が十分に確保される。 When the patch obtained by the present invention is a poultice, the base for the patch obtained by the present invention contains water (purified water). The water content is preferably 20 to 95% by mass, more preferably 25 to 90% by mass, based on the total mass of the base. As a result, the adhesive strength of the polyacrylic acid and the neutralized polyacrylic acid is sufficiently secured.
さらに、本発明によって得られる貼付剤用基剤には、本発明の効果を損なわない範囲において、溶解補助剤、保湿剤、安定化剤、無機粉体、着色料、着香料、pH調整剤等の各種添加剤が含まれていてもよい。 Further, the base for the patch obtained by the present invention includes a solubilizing agent, a moisturizer, a stabilizer, an inorganic powder, a coloring agent, a fragrance, a pH adjuster, etc. Various additives may be contained.
次に、本発明の貼付剤の製造方法について説明する。本発明の貼付剤の製造方法は、支持体上に基剤と薬物とを含有する膏体層を備える貼付剤の製造方法であって、
前記本発明の貼付剤用基剤の製造方法により前記基剤を調製し、該基剤と前記薬物とを含有する前記膏体層を形成し、該膏体層上に前記支持体を積層する方法である。
Next, the method for producing the patch of the present invention will be described. The method for producing a patch of the present invention is a method for producing a patch having a plaster layer containing a base and a drug on a support.
The base is prepared by the method for producing a base for a patch of the present invention, the plaster layer containing the base and the drug is formed, and the support is laminated on the plaster layer. The method.
前記支持体としては、一般に貼付剤に用いられるものであれば特に制限はなく、例えば、織布(編布等)、不織布、樹脂フィルム、発泡シート、紙が挙げられる。織布、不織布、樹脂フィルムの材質としては特に制限はないが、例えば、ポリエチレン、ポリプロピレン、ポリブチレン等のポリオレフィン;ポリエチレンテレフタレート等のポリエステル;レーヨン、ポリウレタン、及び綿が挙げられる。 The support is not particularly limited as long as it is generally used as a patch, and examples thereof include woven fabrics (knitted fabrics and the like), non-woven fabrics, resin films, foam sheets, and papers. The material of the woven fabric, the non-woven fabric, and the resin film is not particularly limited, and examples thereof include polyolefins such as polyethylene, polypropylene, and polybutylene; polyesters such as polyethylene terephthalate; rayon, polyurethane, and cotton.
本発明によって得られる貼付剤においては、前記支持体の少なくとも一方の面上に前記本発明の貼付剤用基剤の製造方法によって得られる基剤と薬物(薬理活性物質)とを含有する膏体層が形成されている。前記薬物としては一般に貼付剤に用いられるものであれば特に制限はなく、例えば、フェルビナク、フルルビプロフェン、ジクロフェナク、ジクロフェナクナトリウム、サリチル酸メチル、サリチル酸グリコール、インドメタシン、ケトプロフェン等の非ステロイド系抗炎症剤又はこれらのエステル、ジフェンヒドラミン等の抗ヒスタミン剤、アスピリン、アセトアミノフェン、イブプロフェン、ロキソプロフェンナトリウム等の鎮痛剤、リドカイン等の局所麻酔剤、塩化スキサメトニウム等の筋弛緩剤、クロトリマゾール等の抗真菌剤、クロニジン等の降圧剤、ニトログリセリン、硝酸イソソルビド等の血管拡張剤、ビタミンA、ビタミンE(トコフェロール)、トコフェロール酢酸エステル、ビタミンK、オクトチアミン、リボフラビン酪酸エステル等のビタミン類;プロスタグランジン類、スコポラミン、フェンタニル、トウガラシエキス、ノニル酸ワニリルアミドが挙げられる。 In the patch obtained by the present invention, a plaster containing a base and a drug (pharmacologically active substance) obtained by the method for producing a base for a patch of the present invention on at least one surface of the support. Layers are formed. The drug is not particularly limited as long as it is generally used as a patch, and is, for example, a non-steroidal anti-inflammatory agent such as fervinac, flurbiprofen, diclofenac, diclofenac sodium, methyl salicylate, glycol salicylate, indomethacin, and ketoprofen. Alternatively, these esters, antihistamines such as difenhydramine, analgesics such as aspirin, acetaminophen, ibuprofen, and sodium loxoprofen, local anesthetics such as lidocaine, muscle relaxants such as schisametonium chloride, antifungal agents such as clotrimazole, and clonidine. Antihypertensive agents such as, nitroglycerin, vasodilators such as isosorbide nitrate, vitamins such as vitamin A, vitamin E (tocopherol), tocopherol acetate, vitamin K, octothiamine, riboflavin butyrate; prostaglandins, scopolamine, etc. Examples include fentanyl, indomethacin extract, and nonylate vanillylamide.
また、本発明によって得られる貼付剤においては、前記膏体層の前記支持体とは反対側の面に剥離ライナーを備えていてもよい。この剥離ライナーは膏体層を被覆して保護するものである。このような剥離ライナーとしては一般に貼付剤に用いられるものであれば特に制限はなく、例えば、ポリエステル(ポリエチレンテレフタレート、ポリブチレンテレフタレート、ポリエチレンナフタレート等)、ポリオレフィン(ポリエチレン、ポリプロピレン、ポリブチレン等)等の樹脂フィルム;紙等が挙げられる。 Further, in the patch obtained by the present invention, a release liner may be provided on the surface of the plaster layer opposite to the support. This release liner coats and protects the plaster layer. The peeling liner is not particularly limited as long as it is generally used as a patch, and for example, polyester (polyethylene terephthalate, polybutylene terephthalate, polyethylene naphthalate, etc.), polyolefin (polyethylene, polypropylene, polybutylene, etc.), etc. Resin film; examples include paper.
本発明の貼付剤の製造方法としては特に制限はなく、一般の貼付剤の製造方法を採用することができる。例えば、前記本発明の貼付剤用基剤の製造方法によって得られる基剤及び薬物を含有する膏体を調製し、この膏体を剥離ライナー上に均一に展延した後、支持体を積層することによって支持体上に前記膏体層を備える貼付剤が得られる。 The method for producing the patch of the present invention is not particularly limited, and a general method for producing the patch can be adopted. For example, a plaster containing the base and the drug obtained by the method for producing a base for a patch of the present invention is prepared, the plaster is uniformly spread on a release liner, and then the support is laminated. As a result, a patch having the plaster layer on the support can be obtained.
以下、実施例及び比較例に基づいて本発明をより具体的に説明するが、本発明は以下の実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail based on Examples and Comparative Examples, but the present invention is not limited to the following Examples.
(試験例1)
ゼラチン1〜5質量部を精製水99〜95質量部に添加して溶解し、総量100質量部の試料溶液を調製した。この試料溶液について官能試験を行い、下記の判定基準に基づいて、0〜100の間で臭いを評価した。この官能試験を被験者5人について行い、臭いスコアの平均値を求めた。その結果を表1に示す。
〔判定基準〕
100:非常に不快に感じる。
75:不快に感じる。
50:感じるが不快ではない。
25:わずかに感じる。
0:感じない。
(Test Example 1)
1 to 5 parts by mass of gelatin was added to 99 to 95 parts by mass of purified water and dissolved to prepare a sample solution having a total amount of 100 parts by mass. A sensory test was performed on this sample solution, and the odor was evaluated between 0 and 100 based on the following criteria. This sensory test was performed on 5 subjects, and the average value of the odor score was calculated. The results are shown in Table 1.
[Criteria]
100: I feel very uncomfortable.
75: I feel uncomfortable.
50: Feels but not unpleasant.
25: I feel a little.
0: I don't feel it.
(試験例2)
ゼラチンの代わりにポリビニルアルコール(PVA)を用いた以外は試験例1と同様にして官能試験を被験者5人について行い、臭いスコアの平均値を求めた。その結果を表1に示す。
(Test Example 2)
A sensory test was conducted on 5 subjects in the same manner as in Test Example 1 except that polyvinyl alcohol (PVA) was used instead of gelatin, and the average value of the odor score was calculated. The results are shown in Table 1.
(試験例3)
ゼラチンの代わりにポリアクリル酸(PAA)を用いた以外は試験例1と同様にして官能試験を被験者5人について行い、臭いスコアの平均値を求めた。その結果を表1に示す。
(Test Example 3)
A sensory test was conducted on 5 subjects in the same manner as in Test Example 1 except that polyacrylic acid (PAA) was used instead of gelatin, and the average value of the odor score was calculated. The results are shown in Table 1.
表1に示したように、ゼラチン及びポリビニルアルコールが臭いの原因物質であることがわかった。また、ゼラチン及びポリビニルアルコールの含有量がそれぞれ2質量%以上及び1質量%以上になると、不快に感じることがわかった。 As shown in Table 1, gelatin and polyvinyl alcohol were found to be odor-causing substances. It was also found that when the contents of gelatin and polyvinyl alcohol were 2% by mass or more and 1% by mass or more, respectively, it felt unpleasant.
(実施例1)
先ず、ゼラチン2質量部、ポリビニルアルコール(PVA)1質量部、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョン(日本カーバイド工業株式会社製「ニカゾールTS−620」)0.6質量部(固形物基準)、L−メンチルグリセリルエーテル1質量部、ポリアクリル酸ナトリウム(PANa)1質量部、ケイ酸マグネシウム0.1質量部、及び精製水94.3質量部を混合して攪拌し、基剤を調製した。
(Example 1)
First, 2 parts by mass of gelatin, 1 part by mass of polyvinyl alcohol (PVA), and 0.6 parts by mass (solid) of methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion ("Nicazole TS-620" manufactured by Nippon Carbide Industries, Ltd.). Material standard), 1 part by mass of L-menthylglyceryl ether, 1 part by mass of sodium polyacrylate (PANA), 0.1 part by mass of magnesium silicate, and 94.3 parts by mass of purified water are mixed and stirred, and the base is used. Was prepared.
得られた基剤をパップ剤1枚(140mm×100mm)当たり7gとなるように剥離ライナー上に均一に展延した。その上に、直ちに支持体を積層し、パップ剤を得た。 The obtained base was uniformly spread on the release liner so as to be 7 g per one poultice (140 mm × 100 mm). A support was immediately laminated on the support to obtain a poultice.
(実施例2〜16)
ゼラチン、ポリビニルアルコール(PVA)、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョン、及び精製水の配合量を表2に示す配合量に変更した以外は実施例1と同様にして基剤を調製し、さらにパップ剤を作製した。
(Examples 2 to 16)
The base was prepared in the same manner as in Example 1 except that the amounts of gelatin, polyvinyl alcohol (PVA), methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion, and purified water were changed to the amounts shown in Table 2. It was prepared and a poultice was prepared.
(比較例1)
アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの代わりにアミノアルキルメタクリレートコポリマーE(エボニック社製「オイドラギットEPO」)12質量部を用いた以外は実施例4と同様にして基剤を調製し、さらにパップ剤を作製した。
(Comparative Example 1)
A base was prepared in the same manner as in Example 4 except that 12 parts by mass of aminoalkyl methacrylate copolymer E (“Eudragit EPO” manufactured by Ebonic) was used instead of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion. , Further, a poultice was prepared.
(比較例2)
アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの代わりにメタクリル酸ブチル−メタクリル酸メチルコポリマー(エボニック社製「Plastoid B」)12質量部を用いた以外は実施例4と同様にして基剤を調製し、さらにパップ剤を作製した。
(Comparative Example 2)
Base in the same manner as in Example 4 except that 12 parts by mass of butyl methacrylate-methyl methacrylate copolymer (“Plastoid B” manufactured by Evonik Industries, Inc.) was used instead of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion. Was prepared, and a poultice was further prepared.
(比較例3〜13)
ゼラチン、ポリビニルアルコール(PVA)、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョン、及び精製水の配合量を表3に示す配合量に変更した以外は実施例1と同様にして基剤を調製し、さらにパップ剤を作製した。
(Comparative Examples 3 to 13)
The base was prepared in the same manner as in Example 1 except that the amounts of gelatin, polyvinyl alcohol (PVA), methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion, and purified water were changed to the amounts shown in Table 3. It was prepared and a poultice was prepared.
<粘着性試験>
得られたパップ剤を25mm×90mmの矩形に切り抜き、サインカーブからなる傾斜台下の水平な底部に配置し、剥離ライナーを除去して基剤層を露出させた。次いで、前記傾斜台の傾斜面に17号鋼球(直径:17/32インチ)を転がし、前記基剤層表面上で鋼球が停止するまでの距離(停止距離)を測定した。この測定を3回繰り返し、その平均値(単位:mm)を算出した。その結果を表4〜表7に示す。なお、前記基剤層表面上で鋼球が停止しなかったものについては、「90<」と表記した。この停止距離が短いものほど、基剤層の粘着力が高いものであると判断され、停止距離が90mm以下であれば粘着力は製剤として許容できる。ただし、停止距離が短くなりすぎると、粘着力が強くなりすぎ、剥離時の痛みを許容できないため、停止距離は20mm以上であることが好ましい。
<Adhesiveness test>
The obtained poultice was cut out into a rectangle of 25 mm × 90 mm and placed on a horizontal bottom under an inclined table composed of a sine curve, and a release liner was removed to expose the base layer. Next, a No. 17 steel ball (diameter: 17/32 inch) was rolled on the inclined surface of the inclined table, and the distance (stop distance) until the steel ball stopped on the surface of the base layer was measured. This measurement was repeated 3 times, and the average value (unit: mm) was calculated. The results are shown in Tables 4 to 7. In addition, when the steel ball did not stop on the surface of the base layer, it was described as "90 <". It is judged that the shorter the stopping distance is, the higher the adhesive strength of the base layer is, and if the stopping distance is 90 mm or less, the adhesive strength is acceptable as a preparation. However, if the stopping distance is too short, the adhesive strength becomes too strong and pain at the time of peeling cannot be tolerated. Therefore, the stopping distance is preferably 20 mm or more.
<官能試験>
得られたパップ剤について官能試験を行い、下記の判定基準に基づいて、0〜100の間で臭いスコアとして評価した。この官能試験を被験者5人について行い、臭いスコアの平均値を求めた。その結果を表4〜表7に示す。なお、前記粘着性試験の結果が「90<」又は20mm未満のものについては官能試験を実施しなかった。
〔判定基準〕
100:非常に不快に感じる。
75:不快に感じる。
50:感じるが不快ではない。
25:わずかに感じる。
0:感じない。
<Sensory test>
The obtained poultice was subjected to a sensory test and evaluated as an odor score between 0 and 100 based on the following criteria. This sensory test was performed on 5 subjects, and the average value of the odor score was calculated. The results are shown in Tables 4 to 7. The sensory test was not carried out when the result of the adhesiveness test was "90 <" or less than 20 mm.
[Criteria]
100: I feel very uncomfortable.
75: I feel uncomfortable.
50: Feels but not unpleasant.
25: I feel a little.
0: I don't feel it.
表4に示した結果から明らかなように、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョン(実施例4)を用いることによって、ゼラチン及びPVAに由来する製剤臭をマスキングできる(臭いスコア50以下)ことが確認された。一方、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの代わりにアミノアルキルメタクリレートコポリマーE(比較例1)又はメタクリル酸ブチル−メタクリル酸メチルコポリマー(比較例2)を用いた場合には、製剤臭をマスキングすることができなかった(臭いスコア50超過)。 As is clear from the results shown in Table 4, the formulation odor derived from gelatin and PVA can be masked by using the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion (Example 4) (odor score 50). The following) was confirmed. On the other hand, when aminoalkyl methacrylate copolymer E (Comparative Example 1) or butyl methacrylate-methyl methacrylate copolymer (Comparative Example 2) is used instead of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion, the preparation is prepared. The odor could not be masked (odor score exceeded 50).
表5に示した結果から明らかなように、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの含有量(固形物基準)を基剤の全質量に対して0.5〜13.0質量%の範囲内(実施例1〜4、6〜10及び12〜16)とすることによって、ゼラチン及びPVAに由来する製剤臭をマスキングでき(臭いスコア50以下)、また、製剤として許容できる粘着力(停止距離20〜90mm)が得られることが確認された。一方、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの含有量(固形物基準)が0.5質量%未満(比較例3、5及び10)になると、製剤臭をマスキングすることができなかった(臭いスコア50超過)。また、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの含有量(固形物基準)が15.0質量%(比較例4)になると、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体自体の臭いが発生する(臭いスコア50超過)ことがわかった。 As is clear from the results shown in Table 5, the content (based on solid matter) of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion is 0.5 to 13.0 mass with respect to the total mass of the base. By setting the content within the range of% (Examples 1 to 4, 6 to 10 and 12 to 16), the odor of the formulation derived from gelatin and PVA can be masked (odor score of 50 or less), and the adhesive strength is acceptable as the formulation. It was confirmed that (stop distance 20 to 90 mm) can be obtained. On the other hand, when the content (based on solid matter) of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion is less than 0.5% by mass (Comparative Examples 3, 5 and 10), the odor of the preparation can be masked. No (smell score exceeded 50). Further, when the content (based on solid matter) of the methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion is 15.0% by mass (Comparative Example 4), the methyl acrylate / 2-ethylhexyl acrylate copolymer itself It was found that the odor of (odor score exceeded 50) was generated.
表6に示した結果から明らかなように、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの含有量(固形物基準)が0.5〜13.0質量%の基剤においては、ゼラチンの含有量を基剤の全質量に対して1.5〜6質量%の範囲内(実施例1〜4、11及び13〜16)とすることによって、ゼラチンに由来する製剤臭をマスキングでき(臭いスコア50以下)、また、製剤として許容できる粘着力(停止距離20〜90mm)が得られることが確認された。一方、ゼラチンの含有量が7.5質量%(比較例11〜14)になると、粘着力が弱く(停止距離90mm超過)、製剤として許容できないものであった。 As is clear from the results shown in Table 6, gelatin is used as a base having a content of methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion (based on solid matter) of 0.5 to 13.0% by mass. By setting the content of the above in the range of 1.5 to 6% by mass (Examples 1 to 4, 11 and 13 to 16) with respect to the total mass of the base, the odor of the formulation derived from gelatin can be masked ( It was confirmed that an odor score of 50 or less) and an adhesive strength (stopping distance of 20 to 90 mm) acceptable as a preparation can be obtained. On the other hand, when the gelatin content was 7.5% by mass (Comparative Examples 11 to 14), the adhesive strength was weak (the stopping distance exceeded 90 mm), which was unacceptable as a preparation.
表7に示した結果から明らかなように、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョンの含有量(固形物基準)が0.5〜13.0質量%の基剤においては、ポリビニルアルコール(PVA)の含有量を基剤の全質量に対して0.5〜8質量%の範囲内(実施例1〜5及び7〜10)とすることによって、PVAに由来する製剤臭をマスキングでき(臭いスコア50以下)、また、製剤として許容できる粘着力(停止距離20〜90mm)が得られることが確認された。一方、PVAの含有量が10質量%(比較例6〜9)になると、剥離時の痛みを許容できなくなるほど、粘着力が強いものであった(停止距離20mm未満)。 As is clear from the results shown in Table 7, polyvinyl is used as a base having a content (based on solid matter) of methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion of 0.5 to 13.0% by mass. By setting the alcohol (PVA) content in the range of 0.5 to 8% by mass (Examples 1 to 5 and 7 to 10) with respect to the total mass of the base, the odor of the formulation derived from PVA is masked. It was confirmed that it was possible (smell score 50 or less) and that an acceptable adhesive strength as a preparation (stop distance 20 to 90 mm) was obtained. On the other hand, when the PVA content was 10% by mass (Comparative Examples 6 to 9), the adhesive strength was so strong that the pain at the time of peeling became unacceptable (stop distance less than 20 mm).
(実施例17)
先ず、ゼラチン2質量部、ポリビニルアルコール(PVA)5質量部、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体エマルジョン(日本カーバイド工業株式会社製「ニカゾールTS−620」)10質量部(固形物基準)、L−メンチルグリセリルエーテル1質量部、ポリアクリル酸ナトリウム(PANa)1質量部、ケイ酸マグネシウム0.1質量部、サリチル酸グリコール2質量部、トコフェロール酢酸エステル1質量部、モノステアリン酸ポリエチレングリコール1質量部、及び精製水76.9質量部を混合して攪拌し、基剤と薬物とを含有する膏体を調製した。
(Example 17)
First, 2 parts by mass of gelatin, 5 parts by mass of polyvinyl alcohol (PVA), and 10 parts by mass of methyl acrylate / 2-ethylhexyl acrylate copolymer emulsion ("Nicazole TS-620" manufactured by Nippon Carbide Industries, Ltd.) (based on solids). ), 1 part by mass of L-menthylglyceryl ether, 1 part by mass of sodium polyacrylate (PANa), 0.1 part by mass of magnesium silicate, 2 parts by mass of glycol salicylate, 1 part by mass of tocopherol acetate, 1 part by mass of polyethylene glycol monostearate. 76.9 parts by mass of purified water and 76.9 parts by mass of purified water were mixed and stirred to prepare a plaster containing a base and a drug.
得られた膏体をパップ剤1枚(140mm×100mm)当たり7gとなるように剥離ライナー上に均一に展延した。その上に、直ちに支持体を積層し、パップ剤を得た。このパップ剤について前記粘着性試験及び前記官能試験を行なった。その結果を表8に示す。 The obtained plaster was uniformly spread on a release liner so as to be 7 g per one poultice (140 mm × 100 mm). A support was immediately laminated on the support to obtain a poultice. The adhesive test and the sensory test were performed on this poultice. The results are shown in Table 8.
表8に示した結果から明らかなように、清涼化剤としてL−メンチルグリセリルエーテルを用いたパップ剤に薬物が含まれる場合(すなわち、基剤と薬物とを含有する膏体層を備えるパップ剤)であっても、膏体層にポリ(アクリル酸メチル/アクリル酸2−エチルヘキシル)共重合体を配合することによって、膏体層の粘着力を保持しつつ、ゼラチン及びポリビニルアルコールから発生する不快な臭いが抑制されることが確認された。 As is clear from the results shown in Table 8, when the drug is contained in the poultice using L-mentylglyceryl ether as the cooling agent (that is, the poultice having a plaster layer containing the base and the drug). ), But by blending a poly (methyl acrylate / 2-ethylhexyl acrylate) copolymer in the plaster layer, the unpleasantness generated from gelatin and polyvinyl alcohol while maintaining the adhesive strength of the plaster layer. It was confirmed that the odor was suppressed.
以上説明したように、本発明によれば、清涼化剤としてL−メンチルグリセリルエーテルを用いた場合であっても、基剤の粘着力を保持しつつ、不快な臭いの発生が抑制された貼付剤用基剤を提供することが可能となる。 As described above, according to the present invention, even when L-menthylglyceryl ether is used as the cooling agent, the application is suppressed from generating an unpleasant odor while maintaining the adhesive strength of the base. It becomes possible to provide an agent base.
したがって、本発明によって得られる貼付剤は、このような基剤を用いて膏体層が形成されているため、刺激臭や製剤臭等の不快な臭いを感じることなく、長時間使用することができる点で有用である。 Therefore, since the patch obtained by the present invention has a plaster layer formed by using such a base, it can be used for a long time without feeling an unpleasant odor such as a pungent odor or a preparation odor. It is useful in that it can be done.
Claims (4)
該基剤の全質量に対して、
前記ゼラチンの含有量が1.5〜6質量%であり、
前記ポリビニルアルコールの含有量が0.5〜8質量%であり、
前記アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体の含有量が0.5〜13質量%であるように、
ゼラチン、ポリビニルアルコール、アクリル酸メチル・アクリル酸2−エチルヘキシル共重合体、及びL−メンチルグリセリルエーテルを混合する、貼付剤用基剤の製造方法。 A method for producing a base containing gelatin, polyvinyl alcohol, 2-ethylhexyl acrylate copolymer, and L-menthylglyceryl ether.
With respect to the total mass of the base
The gelatin content is 1.5 to 6% by mass.
The content of the polyvinyl alcohol is 0.5 to 8% by mass.
So that the content of the methyl acrylate / 2-ethylhexyl acrylate copolymer is 0.5 to 13% by mass.
A method for producing a base for a patch, which comprises mixing gelatin, polyvinyl alcohol, 2-ethylhexyl acrylate copolymer, and L-menthylglyceryl ether.
請求項1又は2に記載の方法により前記基剤を調製し、該基剤と前記薬物とを含有する前記膏体層を形成し、該膏体層上に前記支持体を積層する、貼付剤の製造方法。 A method for producing a patch having a plaster layer containing a base and a drug on a support.
A patch that prepares the base by the method according to claim 1 or 2, forms the plaster layer containing the base and the drug, and laminates the support on the plaster layer. Manufacturing method.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017029841 | 2017-02-21 | ||
| JP2017029841 | 2017-02-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501271A Division JP6622441B2 (en) | 2017-02-21 | 2018-02-15 | Base for patch and patch using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020023586A JP2020023586A (en) | 2020-02-13 |
| JP6778809B2 true JP6778809B2 (en) | 2020-11-04 |
Family
ID=63252615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501271A Active JP6622441B2 (en) | 2017-02-21 | 2018-02-15 | Base for patch and patch using the same |
| JP2019210348A Active JP6778809B2 (en) | 2017-02-21 | 2019-11-21 | A method for producing a base for a patch and a method for producing a patch using a base obtained thereby. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501271A Active JP6622441B2 (en) | 2017-02-21 | 2018-02-15 | Base for patch and patch using the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200009075A1 (en) |
| EP (1) | EP3586833B1 (en) |
| JP (2) | JP6622441B2 (en) |
| KR (1) | KR102125662B1 (en) |
| CN (1) | CN110267653A (en) |
| TW (1) | TWI687230B (en) |
| WO (1) | WO2018155310A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI827775B (en) * | 2018-12-27 | 2024-01-01 | 日商小林製藥股份有限公司 | Patch |
| WO2025164529A1 (en) * | 2024-01-29 | 2025-08-07 | 久光製薬株式会社 | Cataplasm |
| JP7712512B1 (en) * | 2024-01-29 | 2025-07-23 | 久光製薬株式会社 | Poultice |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3219995B2 (en) | 1996-02-08 | 2001-10-15 | 高砂香料工業株式会社 | Refreshing agent |
| JP4587549B2 (en) * | 2000-10-23 | 2010-11-24 | 高砂香料工業株式会社 | 1-halogeno-3-l-menthoxypropan-2-ol |
| JP4799783B2 (en) * | 2001-09-27 | 2011-10-26 | 帝國製薬株式会社 | Elastic patch |
| JP2006001860A (en) * | 2004-06-16 | 2006-01-05 | Shiseido Co Ltd | Slightly water-soluble medicine-containing poultice |
| WO2006090782A1 (en) | 2005-02-23 | 2006-08-31 | Saitama Daiichi Pharmaceutical Co., Ltd. | Composition for hydrous adhesive patch for external use and adhesive patch comprising the composition |
| WO2013191158A1 (en) * | 2012-06-20 | 2013-12-27 | 久光製薬株式会社 | Percutaneous absorption promoter and skin patch comprising same |
| BR112016003675B1 (en) * | 2013-08-23 | 2022-11-22 | Hisamitsu Pharmaceutical Co., Inc | POULTICE AND METHOD FOR PRODUCING THE SAME |
| US9707194B2 (en) * | 2014-02-27 | 2017-07-18 | Hisamitsu Pharmaceutical Co., Inc. | Ketoprofen-containing poultice |
| MA41266A (en) * | 2014-12-22 | 2017-10-31 | Hisamitsu Pharmaceutical Co | POULTICE |
| WO2016104227A1 (en) * | 2014-12-22 | 2016-06-30 | 久光製薬株式会社 | Cataplasm |
| WO2016136556A1 (en) * | 2015-02-24 | 2016-09-01 | 久光製薬株式会社 | Adhesive skin poultice |
-
2018
- 2018-02-15 EP EP18756570.0A patent/EP3586833B1/en active Active
- 2018-02-15 KR KR1020197027488A patent/KR102125662B1/en active Active
- 2018-02-15 WO PCT/JP2018/005337 patent/WO2018155310A1/en not_active Ceased
- 2018-02-15 US US16/483,510 patent/US20200009075A1/en not_active Abandoned
- 2018-02-15 JP JP2019501271A patent/JP6622441B2/en active Active
- 2018-02-15 CN CN201880010858.2A patent/CN110267653A/en active Pending
- 2018-02-21 TW TW107105733A patent/TWI687230B/en active
-
2019
- 2019-11-21 JP JP2019210348A patent/JP6778809B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018155310A1 (en) | 2018-08-30 |
| TWI687230B (en) | 2020-03-11 |
| US20200009075A1 (en) | 2020-01-09 |
| BR112019014346A2 (en) | 2020-02-27 |
| EP3586833B1 (en) | 2021-07-07 |
| KR102125662B1 (en) | 2020-06-22 |
| JPWO2018155310A1 (en) | 2019-11-07 |
| TW201841657A (en) | 2018-12-01 |
| EP3586833A4 (en) | 2020-02-26 |
| JP2020023586A (en) | 2020-02-13 |
| JP6622441B2 (en) | 2019-12-18 |
| CN110267653A (en) | 2019-09-20 |
| KR20190111149A (en) | 2019-10-01 |
| EP3586833A1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5130203B2 (en) | Non-aqueous adhesive composition, patch and method for producing the patch | |
| JP6778809B2 (en) | A method for producing a base for a patch and a method for producing a patch using a base obtained thereby. | |
| JP5396208B2 (en) | Water resistant patch preparation | |
| KR20160046846A (en) | Cataplasm and method for producing same | |
| JP2005519054A (en) | Adhesives and binders for skin or transdermal therapeutic systems | |
| JPH03291217A (en) | Nitroglycerin plaster | |
| TWI884920B (en) | Hydrated adhesive skin patch | |
| JP5015562B2 (en) | Patch preparation | |
| WO2012105618A1 (en) | Patch preparation | |
| JP5185509B2 (en) | Patch | |
| JP7109531B2 (en) | Acrylic patch containing calcium silicate | |
| JPH07103016B2 (en) | Patch and method for producing the same | |
| JP7716386B2 (en) | Patches | |
| JP7135196B2 (en) | METHOD FOR CONTROLLING COLD FLOW OF ACRYLIC PATCH | |
| HK40012487A (en) | Transdermal patch base and transdermal patch using same | |
| JP2007520480A (en) | Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid | |
| CN118742297A (en) | Cataplasm and method for producing the same | |
| BR112019014346B1 (en) | PLASTER BASE AND PLASTER USING THE SAME | |
| JP2022142438A (en) | Water-containing patch with moisture sensor function | |
| JPH082369B2 (en) | External parts | |
| HK40043594A (en) | Water-containing transdermal patch | |
| JP2020055793A (en) | Non-aqueous patch | |
| JP2006151886A (en) | Patch with little exfoliation | |
| JPH0959148A (en) | Plaster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200928 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201012 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6778809 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |